经直肠超声靶目标可见度在预测临床有意义前列腺癌中的增量价值
这项回顾性双中心研究纳入2700例接受认知融合经会阴前列腺穿刺的患者,评估三级分级TRUS靶目标可见度在临床和MRI变量之外的预测增量。加入TRUS可见度后模型预测临床有意义前列腺癌的AUC、平均精度和校准在时间验证与外部验证中均获得轻微但一致的改善。结论为TRUS可见度可用于穿刺后风险细化与取样辅助,不应用于避免穿刺。
要点
- TRUS可见度三级分级可作为临床和MRI之外的额外风险分层信息
- TRUS可见度价值在于细化风险和辅助取样,不应作为免穿刺依据
- 观察者一致性高,线性加权Cohen κ为0.82
核心结论
- TRUS靶目标可见度在临床和MRI变量基础上对患者层面活检检出的临床有意义前列腺癌具有轻微增量预测价值
- 由于临床有意义前列腺癌定义基于靶向或系统穿刺结果,该关联无法区分病变生物学与定位或取样改善
- TRUS可见度的可能作用是风险细化和取样辅助,不能作为避免活检的依据,也不能证明因果获益
研究设计与样本
- 回顾性双中心研究,共纳入2700例接受认知融合经会阴前列腺穿刺的男性
- 中心A提供开发队列1642例和时间验证队列565例,中心B提供外部验证队列493例
- 采用梯度提升模型评估,TRUS可见度由不知病理结果的阅片者根据穿刺计划材料回顾性分级
- 评估指标包括AUC、平均精度、Brier评分、定量校准、决策曲线分析和观察者间一致性
关键影像表现/征象
- TRUS靶目标可见度按三级分级,反映目标在经直肠超声上被识别和定位的清晰程度
- 加入TRUS可见度后校准曲线在时间验证和外部验证中斜率分别为1.160和1.304
- 两验证队列中不同TRUS可见度分级之间的临床有意义前列腺癌风险梯度均保持存在
诊断标准与关键数值
- 时间验证中可见度模型相对临床MRI模型的ΔAUC为0.039(95%CI 0.021–0.058)
- 时间验证中Δ平均精度为0.074(95%CI 0.034–0.116),外部验证为0.045(95%CI 0.014–0.075)
- 时间验证中ΔBrier评分为-0.016(95%CI -0.023至-0.009),外部验证为-0.016(95%CI -0.023至-0.008)
- 外部验证中ΔAUC为0.023(95%CI 0.009–0.037)
- 观察者间一致性以线性加权Cohen κ表示,为0.82
临床应用与阅片要点
- 在经会阴认知融合穿刺计划材料中,可对TRUS可见度进行三级分级作为常规记录
- TRUS可见度不变时可作为风险细化信息补充到临床和MRI综合判断中
- TRUS可见度较好时不应据此省略靶向或系统穿刺
局限性
- TRUS可见度为回顾性分类,基于穿刺计划材料而非实时超声图像
- 临床有意义前列腺癌定义在患者层面,无法区分病变生物学差异与取样或定位改善
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine whether three-level transrectal ultrasound (TRUS) target visibility adds predictive information beyond clinical and magnetic resonance imaging (MRI) variables for patient-level biopsy-detected clinically significant prostate cancer (csPCa).
MATERIALS AND METHODS: This retrospective two-center study included 2,700 men undergoing cognitive transperineal biopsy. Center A provided development (n = 1,642) and temporal validation (n = 565) cohorts, and Center B provided external validation (n = 493). Gradient-boosting models were evaluated. TRUS visibility was retrospectively classified from contemporaneous biopsy-planning materials by readers blinded to pathology. Performance was assessed using AUC, average precision (AP), Brier score, quantitative calibration, exploratory decision-curve analysis, and interobserver reproducibility.
RESULTS: Adding visibility to the Clinical-MRI model produced modest but consistent improvement. In temporal validation, ΔAUC was 0.039 (95 % CI, 0.021-0.058), ΔAP 0.074 (0.034-0.116), and ΔBrier score - 0.016 (-0.023 to - 0.009); corresponding external differences were 0.023 (0.009-0.037), 0.045 (0.014-0.075), and - 0.016 (-0.023 to - 0.008). Calibration intercept/slope for the visibility model were - 0.074/1.160 temporally and 0.316/1.304 externally. Visibility-specific csPCa gradients were preserved in both validation cohorts, with no evidence of center-by-visibility heterogeneity. Interobserver agreement was high (linear-weighted Cohen's κ = 0.82).
CONCLUSION: TRUS target visibility provides modest incremental post-TRUS risk information beyond clinical and MRI variables. Because csPCa was defined at the patient level from targeted or systematic cores, the observed association cannot distinguish lesion biology from improved localization or sampling. Its potential role is risk refinement and sampling assistance, not biopsy avoidance or evidence of causal benefit.
引用
- Tang, Chen, Wu, et al. Incremental Value of Transrectal Ultrasound Target Visibility Beyond Clinical and MRI Variables for Predicting Biopsy-Detected Clinically Significant Prostate Cancer: Temporal and External Validation. Eur J Radiol. 2026. PMID: 42800240. doi:10.1016/j.ejrad.2026.113255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。